What is Dendritic cell based Immunotherapy and T cell Adoptive Transfer therapy.

In this blog we are going to serve the details of dendritic cell based Antibody Drug Conjugate and Adoptive T cell transfer therapy.

Regarding dendritic cell based therapy; one must know that dendritic cells have the ability to be stimulated to produce a cytotoxic response towards a certain antigen.

Mainly for this to happen, dendritic cells which are a type of cells that present antigens, are collected from a patient. Then these cells are either transfected with a unit of a virus or are pulsed with an antigen. When the sample is reintroduced into the patient, as a result of the activation of these cells, they present the tumor antigen into the lymphocyte effector, which is made of CD4, CD8, T Cells, and B cells.

www.gapsos.com

This leads to an initiation of a cytotoxic response to the cells that are expressing the tumor antigen. An example of this approach is Sipuleucel T which is used mainly to treat patients with metastatic prostate cancer (HRPC).

On the other hand, the Adoptive T cell transfer, is mainly the transfer of T cells to produce a cytotoxic effect to attack cancerous cells, naturally these types of cells are reactive to cancerous cells. To introduce them to patients, they are generated in vitro and then re-introduced to the patient.

An example of this was shown in a study where there is introduction of lymphocytes that were autologous and tumor penetrating as an effective treatment for metastatic melanoma. In accordance to this procedure, the following must occur:

First the T cells that are inside the tumor within the patient must be extracted. Then these T cells are trained to battle the tumor cells, usually these are referred to Tumor infiltrating lymphocytes (TIL).

Then they are grown in vitro using high concentration. Of allo-reactive feeder cells, IL2, & anti CD3. Then these T cells are transferred back and introduced into the patient with the administration of IL2 exogenously to further increase noticeably their anti-effect on cancer. This leads to about a 51 % objective response rate, and in some cases the tumors were undetectable in size.

Thus, in this way it has been introduced the details of dendritic cell based therapy and adoptive T cell transfer and it’s used for treatment.

Global Allied Pharmaceuticals is providing immunotherapy and immune-oncology services since more than 14 years. Contact us at www.gapsos.com.